MapLight Therapeutics Inc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2026 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from __________ to __________Commission File Number: 001-42914 MapLight Therapeutics, Inc.(Exact Name of Registrant as Specified in its Charter) 83-2163243(I.R.S. EmployerIdentification No.) Delaware( State or other jurisdiction ofincorporation or organization) 800 Chesapeake DriveRedwood City, California(Address of principal executive offices) (617) 984-6300(Registrant's telephone number, including area code)N/A(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredVoting Common Stock, par value $0.0001 per shareMPLTNasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and"emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of August 7, 2026, the registrant had 46,377,832 shares of common stock, $0.0001 par value per share, outstanding, of which43,650,321 shares were Voting Common Stock and 2,727,511 shares were Non-Voting Common Stock. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)1Condensed Consolidated Balance Sheets as of June 30, 2026 and December 31, 2025 (Unaudited)1Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months endedJune 30, 2026 and 2025 (Unaudited)2Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)for the three and six months ended June 30, 2026 and 2025 (Unaudited)3Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 (Unaudited)4Notes to Unaudited Condensed Consolidated Financial Statements5Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations16Item 3.Quantitative and Qualitative Disclosures About Market Risk26Item 4.Controls and Procedures27 PART II.OTHER INFORMATION Item 1.Legal Proceedings28Item 1A.Risk Factors28Item 2.Unregistered Sales of Equity Securities and Use of Proceeds73Item 3.Defaults Upon Senior Securities73Item 4.Mine Safety Disclosures73Item 5.Other Information73Item 6.Exhibits74Signatures75 PART I—FINANCIAL INFORMATION MapLight Therapeutics, Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share amounts)(Unaudited) The accompanying notes are an integral part of these condensed consolidated financial statements. MapLight Therapeutics, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss(in thousands, except share and per share amounts)(Unaudited) MapLight Therapeutics, Inc.Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)(in thousands, except share amounts)(Unaudited) The accompanying notes are an integral part of these condensed consolidated financial statements. MapLight Therapeutics, Inc.Condensed Consolidated Statements of Cash Flows(in thousands)(Unaudited) MapLight Therapeutics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements(Unaudited) 1.Nature of the Business MapLight Therapeutics, Inc. ("MapLight" or the "Company") was incorporated in November 2018 as Alvarado Therapeutics,Inc., a Delaware corporation. In August 2019, the Company changed its name to MapLight Therapeutics, Inc.